SCHEMBL3338682

SCHEMBL3338682

CC(C)(C)C1CN(c2c[nH]c3ccccc23)CCN1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.42
CYP2C19 P33261 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
KDM4E B2RXH2 3/20 0.39
ALDH1A1 P00352 2/20 0.39
BRD4 O60885 1/20 0.39
POLB P06746 1/20 0.39
CREBBP Q92793 1/20 0.39
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
PBRM1 Q86U86 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNA7 P36544 1/20 0.37
CHRNA4 P43681 1/20 0.37
HTR3A P46098 1/20 0.37
HTR3D Q70Z44 1/20 0.37
HTR3C Q8WXA8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4558300 0.79 SLC6A9 (0.44) CYP2D6KDM4EALDH1A1HTR3EHTR3B
SCHEMBL16801612 0.78 BRD4 (0.47) GFERCYP2C19CYP2D6CYP2C9KDM4E
SCHEMBL21758469 0.78 BRD4 (0.47) GFERCYP2C19CYP2D6CYP2C9KDM4E
SCHEMBL29252729 0.76 AGTR2 (0.48) ALDH1A1MEN1KMT2A
SCHEMBL30881604 0.76 ADRA2C (0.45) KDM4EALDH1A1BRD4POLBMEN1
SCHEMBL17491559 0.76 ADRA2C (0.45) KDM4EALDH1A1BRD4POLBMEN1
SCHEMBL4527918 0.75 ADRB2 (0.46) MEN1KMT2A
SCHEMBL2327343 0.75 RBP4 (0.37) ALDH1A1POLBMEN1KMT2A
SCHEMBL16801772 0.74 PREP (0.43) GFERCYP2C19CYP2D6CYP2C9KDM4E
SCHEMBL20142570 0.74 KEAP1 (0.38) GOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-06-17 US disclosed
US-7696229-B2 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-13 US disclosed
EP-1984351-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY Memory Pharmaceuticals Corporation (US) 2008-10-29 EP disclosed
US-20080039462-A1 Compounds having 5-HT6 receptor affinity MEMORY PHARMACEUTICALS CORPORATION 2008-02-14 US disclosed
WO-2007098418-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152177-A1 COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR3B, HTR1B GFER 1015/4885CYP2C19 398/4885CYP2D6 87/4885
US-20080039462-A1 Compounds having 5-HT6 receptor affinity HTR6, HTR3B, HTR1B GFER 1015/4885CYP2C19 398/4885CYP2D6 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.